Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron, a biopharmaceutical company, has enrolled the first multiple myeloma patient in a Phase I trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.
Subscribe to our email newsletter
The primary objective of the Phase I dose escalation study is to determine the safety, maximum tolerated dose and objective response rate of GRN163L when administered intravenously in combination with bortezomib with and without dexamethasone in patients with relapsed or refractory disease.
This is the second trial to be conducted of GRN163L in multiple myeloma. A Phase I single agent study initiated is ongoing.
Fabio Benedetti, chief medical officer of oncology at Geron, said: “We have been able to draw on our experience to date with GRN163L from our ongoing single agent studies, including in multiple myeloma, for critical aspects of the design of this combination trial. Our clinical program for this drug now includes six active trials evaluating GRN163L as either a single agent or in combination with current treatment regimens.”